<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15560849</article-id><article-id pub-id-type="pmc">PMC535940</article-id><article-id pub-id-type="publisher-id">1471-2407-4-84</article-id><article-id pub-id-type="doi">10.1186/1471-2407-4-84</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>SMAC is expressed <italic>de novo </italic>in a subset of cervical cancer tumors</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Espinosa</surname><given-names>Magali</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>maggiec73@hotmail.com</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Cantu</surname><given-names>David</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>dcantu3@excite.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Lopez</surname><given-names>Carlos M</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>carlos2724mx@yahoo.com.mx</email></contrib><contrib id="A4" contrib-type="author"><name><surname>De la Garza</surname><given-names>Jaime G</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jgdelagarza@starnet.net.mx</email></contrib><contrib id="A5" corresp="yes" contrib-type="author"><name><surname>Maldonado</surname><given-names>Vilma A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>vilmaml@yahoo.com</email></contrib><contrib id="A6" corresp="yes" contrib-type="author"><name><surname>Melendez-Zajgla</surname><given-names>Jorge</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jorgezajgla@ssa.gob.mx</email></contrib></contrib-group><aff id="I1"><label>1</label>Subdirecci&#x000f3;n de Investigaci&#x000f3;n B&#x000e1;sica. Instituto Nacional de Cancerolog&#x000ed;a. Av. San Fernando # 22. Tlalpan 14080 M&#x000e9;xico, D.F. MEXICO</aff><pub-date pub-type="collection"><year>2004</year></pub-date><pub-date pub-type="epub"><day>23</day><month>11</month><year>2004</year></pub-date><volume>4</volume><fpage>84</fpage><lpage>84</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/4/84"/><history><date date-type="received"><day>3</day><month>8</month><year>2004</year></date><date date-type="accepted"><day>23</day><month>11</month><year>2004</year></date></history><copyright-statement>Copyright &#x000a9; 2004 Espinosa et al; licensee BioMed Central Ltd.</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license><abstract><sec><title>Background</title><p>Smac/Diablo is a recently identified protein that is released from mitochondria after apoptotic stimuli. It binds IAPs, allowing caspase activation and cell death. In view of its activity it might participate in carcinogenesis. In the present study, we analyzed Smac expression in a panel of cervical cancer patients.</p></sec><sec sec-type="methods"><title>Methods</title><p>We performed semi quantitative RT-PCR on 41 cervical tumor and 6 normal tissue samples. The study included 8 stage I cases; 16 stage II; 17 stage III; and a control group of 6 samples of normal cervical squamous epithelial tissue.</p></sec><sec><title>Results</title><p>Smac mRNA expression was below the detection limit in the normal cervical tissue samples. In contrast, 13 (31.7%) of the 41 cervical cancer biopsies showed detectable levels of this transcript. The samples expressing Smac were distributed equally among the stages (5 in stage I, 4 in stage II and 4 in stage III) with similar expression levels. We found no correlation between the presence of Smac mRNA and histology, menopause, WHO stage or disease status.</p></sec><sec><title>Conclusions</title><p>Smac is expressed <italic>de novo </italic>in a subset of cervical cancer patients, reflecting a possible heterogeneity in the pathways leading to cervical cancer. There was no correlation with any clinical variable.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Apoptosis is an evolutionarily conserved biological process that plays a fundamental role in development and tissue homeostasis in metazoans [<xref ref-type="bibr" rid="B1">1</xref>]. This type of cell death is executed by a family of proteases known as caspases [<xref ref-type="bibr" rid="B2">2</xref>]. There are two well-characterized apoptotic pathways that converge in caspase activation: the death receptor pathway and the mitochondrial pathway [<xref ref-type="bibr" rid="B3">3</xref>]. Inhibitors of Apoptosis Proteins (IAPs) are the most important regulators of caspases. These proteins inhibit caspase activation, thus preventing the induction of apoptosis [<xref ref-type="bibr" rid="B4">4</xref>]. In cells undergoing apoptosis, IAPs are inactivated by interaction with proteins containing the so-called IBM (IAP-binding motif) [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>].</p><p>One IBM protein is the recently identified Smac/DIABLO [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. Smac resides in the mitochondrial intermembrane space in healthy cells but is released into the cytosol during apoptosis, where it interacts with IAPs and disrupts their ability to bind caspases [<xref ref-type="bibr" rid="B8">8</xref>]. Smac is expressed ubiquitously, with high expression in adult testis, heart, liver, kidney, spleen, prostate and ovary and low expression in brain, lung, thymus, and peripheral blood leukocytes [<xref ref-type="bibr" rid="B9">9</xref>]. It is encoded in a nuclear gene and is post-translationally imported into the mitochondria via a targeting sequence in its amino terminus. Removal of this signal generates a mature polypeptide with the IBM at the amino terminal end [<xref ref-type="bibr" rid="B10">10</xref>]. Smac interacts with all mammalian IAPs examined so far: XIAP, cIAP-1, cIAP-2, survivin and ML-IAP [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. The structure of the Smac-XIAP complex has been studied by X-ray crystallography [<xref ref-type="bibr" rid="B13">13</xref>] and high-resolution NMR [<xref ref-type="bibr" rid="B14">14</xref>]; it appears that the tetrapeptide AVPI is indispensable for the formation of this complex.</p><p>IAPs are highly expressed in human tumor cells [<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B17">17</xref>], contributing to the intrinsic resistance of these cells to endogenous death receptor-induced apoptosis and consequently to chemotherapy [<xref ref-type="bibr" rid="B18">18</xref>]. For this reason, peptides mimicking the action of Smac have been generated and analyzed. Four publications to date have shown promising effects of these Smac peptides <italic>in vitro </italic>and <italic>in vivo</italic>; however, further studies are required prior to clinical testing [<xref ref-type="bibr" rid="B19">19</xref>-<xref ref-type="bibr" rid="B22">22</xref>].</p><p>Recently, Sekimura and colleagues found that Smac expression was significantly lower in primary lung cancers than in normal tissue [<xref ref-type="bibr" rid="B23">23</xref>]; patients with lower Smac mRNA levels had worse prognoses. These results indicate that Smac expression may play a role in the progression of primary lung cancer and may be useful for prognosis [<xref ref-type="bibr" rid="B23">23</xref>]. However, Smac expression has not been analyzed in other tumors. In view of the possible role of Smac in cervical carcinogenesis and its potential as a therapeutic target, we have investigated the expression of this apoptotic protein in cervical cancer patients.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Cell lines and tumor samples</title><p>Cervical cancer cell lines (HeLa, SiHa, CaSki and CaLo) were obtained from ATCC and cultured as monolayers in Dulbecco Modified Eagle's Medium (DMEM) containing 10% (V/V) fetal bovine serum (GIBCO, Bethesda, MD, USA) at 37&#x000b0;C in a humidified atmosphere of 5% (V/V) CO<sub>2</sub>.</p><p>Forty-one cervical cancer samples were obtained from the Instituto Nacional de Cancerologia of Mexico. Written consent was obtained from patients before the samples were collected. Tumors were staged according to the International Gynecology and Obstetric Federation (FIGO) system. The samples comprised 8 at stage IB, 16 at stage IIB and 17 at stage IIIB; and a control group comprising 6 samples of normal cervical squamous epithelial tissue (Table <xref ref-type="table" rid="T1">1</xref>). The control samples were derived from hysterectomy specimens from patients with uterine myomatosis. Only samples with normal pathological reports were included.</p></sec><sec><title>Histology</title><p>Histopathological grading was done according to the WHO (World Health Organization) classification system (Table <xref ref-type="table" rid="T1">1</xref>).</p></sec><sec><title>RNA isolation and RT-PCR</title><p>RNA extraction and RT-PCR analysis were performed as described previously [<xref ref-type="bibr" rid="B24">24</xref>]. Briefly, total RNA was extracted from cultured cells, tumors and non-neoplastic tissue samples with Trizol reagent (Invitrogen) following the manufacturer's protocol. RNA purity was confirmed by the 260/280 nm absorbance ratio and its integrity was established with agarose gels. Total RNA (2 &#x003bc;g) was reverse-transcribed in a final 20 &#x003bc;l reaction volume using 15 U ThermoScript reverse transcriptase, 2.5 &#x000d7; RT Buffer and random hexamers (ThermoScript RT-PCR, Invitrogen). The RT-PCR steps were 25&#x000b0;C for 10 min, 50&#x000b0;C for 50 min and 85&#x000b0;C for 5 min. Smac and GAPDH mRNA PCR reactions contained 0.25 &#x003bc;l Amplitaq gold polymerase (Applied Biosystems, ROCHE), 2.5 &#x003bc;l 10 &#x000d7; reaction buffer, 0.5 &#x003bc;l dNTP mix 10 mM, 1 &#x003bc;l sense primer 10 &#x003bc;M, 1 &#x003bc;l anti-sense primer 10 &#x003bc;M and 1 &#x003bc;l cDNA in 25 &#x003bc;l final volume. The Smac primers were: sense 5' GCGCGGATCCATGGCGGCTCTGAAGAGTTG 3' and anti-sense 5' AGCTCTCTAGACTCAGGCCCTCAATCCTCA 3'. The GAPDH primers were: sense 5' CCCCTTCATTGACCTCAACT 3' and antisense 5' TTGTCATGGATGACCTTGGC 3'.</p><p>The PCR cycle parameters for Smac were: 10 min enzyme activation at 95&#x000b0;C followed by 3 cycles of 30 s at 95&#x000b0;C and 2 min at 72&#x000b0;C, then 30 cycles of 30 s at 95&#x000b0;C and 30 s at 68&#x000b0;C, and finally 5 min at 72&#x000b0;C. The corresponding parameters for GAPDH were: 10 min enzyme activation at 95&#x000b0;C followed by 25 cycles of 30 s at 95&#x000b0;C, 30 s at 60&#x000b0;C and 30 s at 72&#x000b0;C. The products were electrophoresed on 1% agarose gels and stained with ethidium bromide. Smac mRNA data were expressed as ratios between the densitometric values (Scion Image software) of Smac gene expression. The PCR products were normalized to the amplified GAPDH, the internal reference gene. Gene expression measurements were repeated at least twice.</p></sec><sec><title>Statistical analysis</title><p>To detect a correlation between pathological tumor parameters and normalized Smac expression we used ANOVA (stage, current disease and menopause status) and <italic>chi </italic>square tests (stage, histology of tumors, menopause and current status). Kaplan-Meier curves for status were generated and log rank was used to test for differences. The mean follow-up was 14.7 months. The statistical package Intercooled Stata 7.0 was used for analyses and statistical significance was accepted when the <italic>p </italic>value was less than 0.05.</p></sec></sec><sec><title>Results</title><p>To ascertain whether Smac is expressed in cervical cancer we performed semiquantitative RT-PCR analyses on a panel of cervical cancer lines, including HeLa, SiHa, CasKi and CaLo cells. As shown in Figure <xref ref-type="fig" rid="F1">1</xref>, the HeLa and CasKi lines contained Smac mRNA, but very low levels were observed in SiHa and CaLo cells.</p><p>Next, we measured Smac mRNA levels using the same approach in 41 cervical tumor and 6 normal cervical samples. To ensure accurate determinations and to verify equal RNA input, GAPDH mRNA was amplified simultaneously. Figure <xref ref-type="fig" rid="F2">2</xref> shows a representative panel of results, which are given in Tables <xref ref-type="table" rid="T1">1</xref> and <xref ref-type="table" rid="T2">2</xref>. Unexpectedly, Smac mRNA was below the detection limit in normal cervical samples. In contrast, as expected from the cell line data, 13 (31.7%) of the 41 cervical cancer biopsies contained detectable levels of this transcript. The samples expressing Smac were distributed equally among the stages (5 in stage I, 4 in stage II and 4 in stage III). We found no significant correlation between Smac mRNA level and histology, menopause, clinical stage or disease status (Table <xref ref-type="table" rid="T2">2</xref>). When the Smac expression levels in the tumor samples were analyzed, there were no significant differences between clinical stages (Figure <xref ref-type="fig" rid="F3">3</xref>), menopause status (Figure <xref ref-type="fig" rid="F4">4</xref>) or disease status (Figure <xref ref-type="fig" rid="F5">5</xref>). Similarly, a survival analysis of the patients showed no statistical differences between patients expressing or not expressing Smac mRNA (Figure <xref ref-type="fig" rid="F6">6</xref>).</p></sec><sec><title>Discussion</title><p>Tumors proliferate beyond the constraints that limit growth in normal tissue. Therefore, the resistance of tumor cells to apoptosis is an essential feature of carcinogenesis. This has been confirmed by the finding that deregulated proliferation alone is not sufficient for tumor formation because there is concomitant induction of cell death [<xref ref-type="bibr" rid="B25">25</xref>]. Overexpression of growth-promoting oncogenes such as c-Myc sensitize cells to apoptosis [<xref ref-type="bibr" rid="B26">26</xref>]. Thus, tumor progression requires the expression of anti-apoptotic proteins or the inactivation of essential pro apoptotic proteins [<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. Indeed, it has been shown that survivin, a member of the Inhibitor of Apoptosis Protein (IAP) family, is upregulated in some tumors [<xref ref-type="bibr" rid="B29">29</xref>], correlating with prognosis [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>].</p><p>Smac is a recently identified proapoptotic protein that interacts with and inhibits several IAPs, including survivin [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. It has been shown that Smac mRNA levels in tumor tissues are significantly lower than in normal tissues [<xref ref-type="bibr" rid="B23">23</xref>]. Patients with lower Smac mRNA levels have worse prognoses. These results indicate that Smac expression may play a role in the progression of primary lung cancer, as expected by the known role of this protein in cell death induced by chemotherapeutic drugs. Unexpectedly, we found that during cancer progression, some cervical tumors express this protein <italic>de novo</italic>.</p><p>Unfortunately, we found no correlation between Smac expression and any clinical variable. This could be attributed to differences in tissue expression of IAPs, which are reported to have different binding affinities for Smac. On the other hand, alternative IAPs such as the recently identified Omi/Htra2 [<xref ref-type="bibr" rid="B32">32</xref>] might play an important tissue- or tumor-specific role. This is supported by the recent report of a null phenotype in Smac-deficient mice, in which a role for other IAP inhibitory proteins is suspected [<xref ref-type="bibr" rid="B33">33</xref>].</p><p>Cancer treatment by chemotherapy and &#x003b3;-irradiation kills cells primarily by the induction of apoptosis. However, few tumors are wholly sensitive to these therapies, and the development of resistance to therapy is an important clinical problem. Failure to activate the apoptotic programme represents an important mode of drug resistance in tumor cells [<xref ref-type="bibr" rid="B34">34</xref>]. Modulation of the key elements in apoptotic signaling should directly influence therapy-induced tumor-cell death. Indeed, it has recently been suggested that peptides mimicking the Smac amino-terminus could be a novel therapeutic weapon [<xref ref-type="bibr" rid="B19">19</xref>]. Tumors with low or null Smac expression, such as the ones reported in this study, could be more susceptible to this approach.</p></sec><sec><title>Conclusions</title><p>During cervical cancer progression, a subset of tumors express the apoptotic protein Smac <italic>de novo</italic>. This finding contrasts with a previous report for lung cancer [<xref ref-type="bibr" rid="B23">23</xref>], underlining the notion that downregulation or even expression of Smac could be dispensable for tumor progression, at least in cervical cancer. This could be because other mitochondrial molecules such as Omi might substitute for its known proapoptotic function. There was no correlation between Smac expression and any clinical variable.</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>JMZ Conceived and coordinated the study.</p><p>VAML: Conceived and coordinated the study. Statistical Analysis</p><p>MEC: Performed RT-PCR assays</p><p>DCL: Provided the clinical samples and coordinated patient study</p><p>CMLG: Coordinated patient assessment, ethical guidelines.</p><p>JGGS: Provided clinical assessment</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/4/84/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was supported by grants <bold>CONACYT-2002-C01-42040/A-1 </bold>and <bold>SALUD-2002-C01-6579 </bold>from Consejo Nacional de Ciencia y Tecnololog&#x000ed;a, M&#x000e9;xico.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uren</surname><given-names>AG</given-names></name><name><surname>Coulson</surname><given-names>EJ</given-names></name><name><surname>Vaux</surname><given-names>DL</given-names></name></person-group><article-title>Conservation of baculovirus inhibitor of apoptosis repeat proteins (BIRPs) in viruses, nematodes, vertebrates and yeasts</article-title><source>Trends Biochem Sci</source><year>1998</year><volume>23</volume><fpage>159</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">9612077</pub-id><pub-id pub-id-type="doi">10.1016/S0968-0004(98)01198-0</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Budihardjo</surname><given-names>I</given-names></name><name><surname>Oliver</surname><given-names>H</given-names></name><name><surname>Lutter</surname><given-names>M</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>Biochemical pathways of caspase activation during apoptosis</article-title><source>Annu Rev Cell Dev Biol</source><year>1999</year><volume>15</volume><fpage>269</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">10611963</pub-id><pub-id pub-id-type="doi">10.1146/annurev.cellbio.15.1.269</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name></person-group><article-title>Mechanisms of caspase activation and inhibition during apoptosis</article-title><source>Mol Cell</source><year>2002</year><volume>9</volume><fpage>459</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">11931755</pub-id><pub-id pub-id-type="doi">10.1016/S1097-2765(02)00482-3</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deveraux</surname><given-names>QL</given-names></name><name><surname>Reed</surname><given-names>JC</given-names></name></person-group><article-title>IAP family proteins--suppressors of apoptosis</article-title><source>Genes Dev</source><year>1999</year><volume>13</volume><fpage>239</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">9990849</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name></person-group><article-title>A conserved tetrapeptide motif: potentiating apoptosis through IAP-binding</article-title><source>Cell Death Differ</source><year>2002</year><volume>9</volume><fpage>93</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">11840157</pub-id><pub-id pub-id-type="doi">10.1038/sj/cdd/4400957</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>C</given-names></name><name><surname>Fang</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition</article-title><source>Cell</source><year>2000</year><volume>102</volume><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">10929711</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(00)00008-8</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verhagen</surname><given-names>AM</given-names></name><name><surname>Ekert</surname><given-names>PG</given-names></name><name><surname>Pakusch</surname><given-names>M</given-names></name><name><surname>Silke</surname><given-names>J</given-names></name><name><surname>Connolly</surname><given-names>LM</given-names></name><name><surname>Reid</surname><given-names>GE</given-names></name><name><surname>Moritz</surname><given-names>RL</given-names></name><name><surname>Simpson</surname><given-names>RJ</given-names></name><name><surname>Vaux</surname><given-names>DL</given-names></name></person-group><article-title>Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins</article-title><source>Cell</source><year>2000</year><volume>102</volume><fpage>43</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">10929712</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(00)00009-X</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Srinivasula</surname><given-names>SM</given-names></name><name><surname>Datta</surname><given-names>P</given-names></name><name><surname>Fan</surname><given-names>XJ</given-names></name><name><surname>Fernandes-Alnemri</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Alnemri</surname><given-names>ES</given-names></name></person-group><article-title>Molecular determinants of the caspase-promoting activity of Smac/DIABLO and its role in the death receptor pathway</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>36152</fpage><lpage>36157</lpage><pub-id pub-id-type="pmid">10950947</pub-id><pub-id pub-id-type="doi">10.1074/jbc.C000533200</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tikoo</surname><given-names>A</given-names></name><name><surname>O'Reilly</surname><given-names>L</given-names></name><name><surname>Day</surname><given-names>CL</given-names></name><name><surname>Verhagen</surname><given-names>AM</given-names></name><name><surname>Pakusch</surname><given-names>M</given-names></name><name><surname>Vaux</surname><given-names>DL</given-names></name></person-group><article-title>Tissue distribution of Diablo/Smac revealed by monoclonal antibodies</article-title><source>Cell Death Differ</source><year>2002</year><volume>9</volume><fpage>710</fpage><lpage>716</lpage><pub-id pub-id-type="pmid">12058276</pub-id><pub-id pub-id-type="doi">10.1038/sj.cdd.4401031.sgm</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chai</surname><given-names>J</given-names></name><name><surname>Du</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>JW</given-names></name><name><surname>Kyin</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name></person-group><article-title>Structural and biochemical basis of apoptotic activation by Smac/DIABLO</article-title><source>Nature</source><year>2000</year><volume>406</volume><fpage>855</fpage><lpage>862</lpage><pub-id pub-id-type="pmid">10972280</pub-id><pub-id pub-id-type="doi">10.1038/35022514</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Z</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name></person-group><article-title>Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>23130</fpage><lpage>23140</lpage><pub-id pub-id-type="pmid">12660240</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M300957200</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vucic</surname><given-names>D</given-names></name><name><surname>Deshayes</surname><given-names>K</given-names></name><name><surname>Ackerly</surname><given-names>H</given-names></name><name><surname>Pisabarro</surname><given-names>MT</given-names></name><name><surname>Kadkhodayan</surname><given-names>S</given-names></name><name><surname>Fairbrother</surname><given-names>WJ</given-names></name><name><surname>Dixit</surname><given-names>VM</given-names></name></person-group><article-title>SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-IAP)</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>12275</fpage><lpage>12279</lpage><pub-id pub-id-type="pmid">11801603</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M112045200</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>G</given-names></name><name><surname>Chai</surname><given-names>J</given-names></name><name><surname>Suber</surname><given-names>TL</given-names></name><name><surname>Wu</surname><given-names>JW</given-names></name><name><surname>Du</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name></person-group><article-title>Structural basis of IAP recognition by Smac/DIABLO</article-title><source>Nature</source><year>2000</year><volume>408</volume><fpage>1008</fpage><lpage>1012</lpage><pub-id pub-id-type="pmid">11140638</pub-id><pub-id pub-id-type="doi">10.1038/35050012</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Olejniczak</surname><given-names>ET</given-names></name><name><surname>Meadows</surname><given-names>RP</given-names></name><name><surname>Betz</surname><given-names>SF</given-names></name><name><surname>Oost</surname><given-names>T</given-names></name><name><surname>Herrmann</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>JC</given-names></name><name><surname>Fesik</surname><given-names>SW</given-names></name></person-group><article-title>Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain</article-title><source>Nature</source><year>2000</year><volume>408</volume><fpage>1004</fpage><lpage>1008</lpage><pub-id pub-id-type="pmid">11140637</pub-id><pub-id pub-id-type="doi">10.1038/35050006</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Cao</surname><given-names>Z</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Wood</surname><given-names>WC</given-names></name></person-group><article-title>Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>6815</fpage><lpage>6824</lpage><pub-id pub-id-type="pmid">14583479</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Iwamoto</surname><given-names>S</given-names></name><name><surname>Gon</surname><given-names>G</given-names></name><name><surname>Nohara</surname><given-names>T</given-names></name><name><surname>Iwamoto</surname><given-names>M</given-names></name><name><surname>Tanigawa</surname><given-names>N</given-names></name></person-group><article-title>Expression of survivin and its relationship to loss of apoptosis in breast carcinomas</article-title><source>Clin Cancer Res</source><year>2000</year><volume>6</volume><fpage>127</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">10656440</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>CG</given-names></name><name><surname>van der Valk</surname><given-names>P</given-names></name><name><surname>Span</surname><given-names>SW</given-names></name><name><surname>Jonker</surname><given-names>JM</given-names></name><name><surname>Postmus</surname><given-names>PE</given-names></name><name><surname>Kruyt</surname><given-names>FA</given-names></name><name><surname>Giaccone</surname><given-names>G</given-names></name></person-group><article-title>Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients</article-title><source>Ann Oncol</source><year>2001</year><volume>12</volume><fpage>799</fpage><lpage>805</lpage><pub-id pub-id-type="pmid">11484955</pub-id><pub-id pub-id-type="doi">10.1023/A:1011167113067</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>X</given-names></name><name><surname>Lei</surname><given-names>L</given-names></name><name><surname>Glas</surname><given-names>R</given-names></name></person-group><article-title>Tumors acquire inhibitor of apoptosis protein (IAP)-mediated apoptosis resistance through altered specificity of cytosolic proteolysis</article-title><source>J Exp Med</source><year>2003</year><volume>197</volume><fpage>1731</fpage><lpage>1743</lpage><pub-id pub-id-type="pmid">12810691</pub-id><pub-id pub-id-type="doi">10.1084/jem.20020801</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arnt</surname><given-names>CR</given-names></name><name><surname>Chiorean</surname><given-names>MV</given-names></name><name><surname>Heldebrant</surname><given-names>MP</given-names></name><name><surname>Gores</surname><given-names>GJ</given-names></name><name><surname>Kaufmann</surname><given-names>SH</given-names></name></person-group><article-title>Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>44236</fpage><lpage>44243</lpage><pub-id pub-id-type="pmid">12218061</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M207578200</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>F</given-names></name><name><surname>Nimmanapalli</surname><given-names>R</given-names></name><name><surname>Paranawithana</surname><given-names>S</given-names></name><name><surname>Wittman</surname><given-names>S</given-names></name><name><surname>Griffin</surname><given-names>D</given-names></name><name><surname>Bali</surname><given-names>P</given-names></name><name><surname>O'Bryan</surname><given-names>E</given-names></name><name><surname>Fumero</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>HG</given-names></name><name><surname>Bhalla</surname><given-names>K</given-names></name></person-group><article-title>Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis</article-title><source>Blood</source><year>2002</year><volume>99</volume><fpage>3419</fpage><lpage>3426</lpage><pub-id pub-id-type="pmid">11964312</pub-id><pub-id pub-id-type="doi">10.1182/blood.V99.9.3419</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Mashima</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Mochizuki</surname><given-names>M</given-names></name><name><surname>Sakamoto</surname><given-names>H</given-names></name><name><surname>Yamori</surname><given-names>T</given-names></name><name><surname>Oh-Hara</surname><given-names>T</given-names></name><name><surname>Tsuruo</surname><given-names>T</given-names></name></person-group><article-title>Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>831</fpage><lpage>837</lpage><pub-id pub-id-type="pmid">12591734</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tamm</surname><given-names>I</given-names></name><name><surname>Trepel</surname><given-names>M</given-names></name><name><surname>Cardo-Vila</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Welsh</surname><given-names>K</given-names></name><name><surname>Cabezas</surname><given-names>E</given-names></name><name><surname>Swatterthwait</surname><given-names>A</given-names></name><name><surname>Arap</surname><given-names>W</given-names></name><name><surname>Reed</surname><given-names>JC</given-names></name><name><surname>Pasqualini</surname><given-names>R</given-names></name></person-group><article-title>Peptides targeting caspase inhibitors</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>14401</fpage><lpage>14405</lpage><pub-id pub-id-type="pmid">12538646</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M210133200</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sekimura</surname><given-names>A</given-names></name><name><surname>Konishi</surname><given-names>A</given-names></name><name><surname>Mizuno</surname><given-names>K</given-names></name><name><surname>Kobayashi</surname><given-names>Y</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Yano</surname><given-names>M</given-names></name><name><surname>Fukai</surname><given-names>I</given-names></name><name><surname>Fujii</surname><given-names>Y</given-names></name></person-group><article-title>Expression of Smac/DIABLO is a novel prognostic marker in lung cancer</article-title><source>Oncol Rep</source><year>2004</year><volume>11</volume><fpage>797</fpage><lpage>802</lpage><pub-id pub-id-type="pmid">15010875</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bandala</surname><given-names>E</given-names></name><name><surname>Espinosa</surname><given-names>M</given-names></name><name><surname>Maldonado</surname><given-names>V</given-names></name><name><surname>Melendez-Zajgla</surname><given-names>J</given-names></name></person-group><article-title>Inhibitor of apoptosis-1 (IAP-1) expression and apoptosis in non-small-cell lung cancer cells exposed to gemcitabine</article-title><source>Biochem Pharmacol</source><year>2001</year><volume>62</volume><fpage>13</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">11377392</pub-id><pub-id pub-id-type="doi">10.1016/S0006-2952(01)00632-3</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evan</surname><given-names>GI</given-names></name><name><surname>Vousden</surname><given-names>KH</given-names></name></person-group><article-title>Proliferation, cell cycle and apoptosis in cancer</article-title><source>Nature</source><year>2001</year><volume>411</volume><fpage>342</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">11357141</pub-id><pub-id pub-id-type="doi">10.1038/35077213</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evan</surname><given-names>GI</given-names></name><name><surname>Wyllie</surname><given-names>AH</given-names></name><name><surname>Gilbert</surname><given-names>CS</given-names></name><name><surname>Littlewood</surname><given-names>TD</given-names></name><name><surname>Land</surname><given-names>H</given-names></name><name><surname>Brooks</surname><given-names>M</given-names></name><name><surname>Waters</surname><given-names>CM</given-names></name><name><surname>Penn</surname><given-names>LZ</given-names></name><name><surname>Hancock</surname><given-names>DC</given-names></name></person-group><article-title>Induction of apoptosis in fibroblasts by c-myc protein</article-title><source>Cell</source><year>1992</year><volume>69</volume><fpage>119</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">1555236</pub-id><pub-id pub-id-type="doi">10.1016/0092-8674(92)90123-T</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stambolic</surname><given-names>V</given-names></name><name><surname>Mak</surname><given-names>TW</given-names></name><name><surname>Woodgett</surname><given-names>JR</given-names></name></person-group><article-title>Modulation of cellular apoptotic potential: contributions to oncogenesis</article-title><source>Oncogene</source><year>1999</year><volume>18</volume><fpage>6094</fpage><lpage>6103</lpage><pub-id pub-id-type="pmid">10557100</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1203126</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ambrosini</surname><given-names>G</given-names></name><name><surname>Adida</surname><given-names>C</given-names></name><name><surname>Altieri</surname><given-names>DC</given-names></name></person-group><article-title>A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma</article-title><source>Nat Med</source><year>1997</year><volume>3</volume><fpage>917</fpage><lpage>921</lpage><pub-id pub-id-type="pmid">9256286</pub-id><pub-id pub-id-type="doi">10.1038/nm0897-917</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reed</surname><given-names>JC</given-names></name></person-group><article-title>The Survivin saga goes in vivo</article-title><source>J Clin Invest</source><year>2001</year><volume>108</volume><fpage>965</fpage><lpage>969</lpage><pub-id pub-id-type="pmid">11581297</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adida</surname><given-names>C</given-names></name><name><surname>Haioun</surname><given-names>C</given-names></name><name><surname>Gaulard</surname><given-names>P</given-names></name><name><surname>Lepage</surname><given-names>E</given-names></name><name><surname>Morel</surname><given-names>P</given-names></name><name><surname>Briere</surname><given-names>J</given-names></name><name><surname>Dombret</surname><given-names>H</given-names></name><name><surname>Reyes</surname><given-names>F</given-names></name><name><surname>Diebold</surname><given-names>J</given-names></name><name><surname>Gisselbrecht</surname><given-names>C</given-names></name><name><surname>Salles</surname><given-names>G</given-names></name><name><surname>Altieri</surname><given-names>DC</given-names></name><name><surname>Molina</surname><given-names>TJ</given-names></name></person-group><article-title>Prognostic significance of survivin expression in diffuse large B-cell lymphomas</article-title><source>Blood</source><year>2000</year><volume>96</volume><fpage>1921</fpage><lpage>1925</lpage><pub-id pub-id-type="pmid">10961895</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adida</surname><given-names>C</given-names></name><name><surname>Recher</surname><given-names>C</given-names></name><name><surname>Raffoux</surname><given-names>E</given-names></name><name><surname>Daniel</surname><given-names>MT</given-names></name><name><surname>Taksin</surname><given-names>AL</given-names></name><name><surname>Rousselot</surname><given-names>P</given-names></name><name><surname>Sigaux</surname><given-names>F</given-names></name><name><surname>Degos</surname><given-names>L</given-names></name><name><surname>Altieri</surname><given-names>DC</given-names></name><name><surname>Dombret</surname><given-names>H</given-names></name></person-group><article-title>Expression and prognostic significance of survivin in de novo acute myeloid leukaemia</article-title><source>Br J Haematol</source><year>2000</year><volume>111</volume><fpage>196</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">11091201</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2141.2000.02328.x</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hegde</surname><given-names>R</given-names></name><name><surname>Srinivasula</surname><given-names>SM</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Wassell</surname><given-names>R</given-names></name><name><surname>Mukattash</surname><given-names>R</given-names></name><name><surname>Cilenti</surname><given-names>L</given-names></name><name><surname>DuBois</surname><given-names>G</given-names></name><name><surname>Lazebnik</surname><given-names>Y</given-names></name><name><surname>Zervos</surname><given-names>AS</given-names></name><name><surname>Fernandes-Alnemri</surname><given-names>T</given-names></name><name><surname>Alnemri</surname><given-names>ES</given-names></name></person-group><article-title>Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>432</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">11606597</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M109721200</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>H</given-names></name><name><surname>Suh</surname><given-names>WK</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Woo</surname><given-names>M</given-names></name><name><surname>Du</surname><given-names>C</given-names></name><name><surname>Elia</surname><given-names>A</given-names></name><name><surname>Duncan</surname><given-names>GS</given-names></name><name><surname>Wakeham</surname><given-names>A</given-names></name><name><surname>Itie</surname><given-names>A</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Mak</surname><given-names>TW</given-names></name></person-group><article-title>Generation and characterization of Smac/DIABLO-deficient mice</article-title><source>Mol Cell Biol</source><year>2002</year><volume>22</volume><fpage>3509</fpage><lpage>3517</lpage><pub-id pub-id-type="pmid">11971981</pub-id><pub-id pub-id-type="doi">10.1128/MCB.22.10.3509-3517.2002</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>R</given-names></name><name><surname>Tanabe</surname><given-names>K</given-names></name><name><surname>Uchida</surname><given-names>Y</given-names></name><name><surname>Emi</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>H</given-names></name><name><surname>Toge</surname><given-names>T</given-names></name></person-group><article-title>Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy</article-title><source>Cancer Chemother Pharmacol</source><year>2002</year><volume>50</volume><fpage>343</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">12439591</pub-id><pub-id pub-id-type="doi">10.1007/s00280-002-0522-7</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><fig position="float" id="F1"><label>Figure 1</label><caption><p>Smac/Diablo mRNA expression in cervical cancer cell lines. Upper panel: RT-PCR analysis of HeLa, SiHa, CasKi and CaLo cervical cancer cell lines. To the left molecular weight marker (100 bp ladder, Invitrogen). Lower panel: RT-PCR of GAPDH, used as a mRNA load control.</p></caption><graphic xlink:href="1471-2407-4-84-1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Smac/Diablo mRNA expression in cervical cancer patients. Upper panel: RT-PCR analysis of Smac/Diablo mRNA. To the left molecular weight marker (100 bp ladder, Invitrogen). Clinical stage is showed at the top of the panel: C: control samples, 1, 2 and 3, clinical stages. Lower panel: RT-PCR of GAPDH, used as a load control.</p></caption><graphic xlink:href="1471-2407-4-84-2"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p>Smac expression levels versus clinical stage of cervical cancer samples. Graph shows median, upper and lower quartiles. P value testing the significance of the difference by ANOVA.</p></caption><graphic xlink:href="1471-2407-4-84-3"/></fig><fig position="float" id="F4"><label>Figure 4</label><caption><p>Smac expression levels versus menopausal status of cervical cancer samples. Graph shows median, upper and lower quartiles. P value testing the significance of the difference by ANOVA.</p></caption><graphic xlink:href="1471-2407-4-84-4"/></fig><fig position="float" id="F5"><label>Figure 5</label><caption><p>Smac expression versus disease status of cervical cancer samples. Graph shows median, upper and lower quartiles. P value testing the significance of the difference by ANOVA.</p></caption><graphic xlink:href="1471-2407-4-84-5"/></fig><fig position="float" id="F6"><label>Figure 6</label><caption><p>Kaplan/Meier survival analysis of cases by Smac expression. Continue black line: Negative expression. Dotted line: Positive expression. Insert in the lower left corner of plot is the P value testing the significance of the difference in the survival curves by the Mantel/Cox log rank test</p></caption><graphic xlink:href="1471-2407-4-84-6"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Smac mRNA expression levels and clinicopathological factors in cervical cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>
                              <italic>Sample</italic>
                           </bold></td><td align="center"><bold>
                              <italic>Age</italic>
                           </bold></td><td align="center"><bold>
                              <italic>Stage</italic>
                           </bold></td><td align="center"><bold>
                              <italic>Histology of tumor</italic>
                           </bold></td><td align="center"><bold>
                              <italic>Menopause</italic>
                           </bold></td><td align="center"><bold>
                              <italic>Current status</italic>
                           </bold></td><td align="center">Smac/<bold><italic>GAPDH</italic></bold></td></tr></thead><tbody><tr><td align="center">Control</td><td align="center">42</td><td></td><td align="center">-</td><td align="left">Menopause</td><td align="left">Disease-free</td><td align="center">0</td></tr><tr><td align="center">Control</td><td align="center">33</td><td></td><td align="center">-</td><td align="left">Pre-menopause</td><td align="left">Disease-free</td><td align="center">0</td></tr><tr><td align="center">Control</td><td align="center">28</td><td></td><td align="center">-</td><td align="left">Pre-menopause</td><td align="left">Disease-free</td><td align="center">0</td></tr><tr><td align="center">Control</td><td align="center">44</td><td></td><td align="center">-</td><td align="left">Menopause</td><td align="left">Disease-free</td><td align="center">0</td></tr><tr><td align="center">Control</td><td align="center">47</td><td></td><td align="center">-</td><td align="left">Menopause</td><td align="left">Disease-free</td><td align="center">0</td></tr><tr><td align="center">Control</td><td align="center">35</td><td></td><td align="center">-</td><td align="left">Pre-menopause</td><td align="left">Disease-free</td><td align="center">0</td></tr><tr><td align="center">1</td><td align="center">46</td><td align="center">I</td><td align="left">Adenocarcinome</td><td align="left">Menopause</td><td align="left">Disease-free</td><td align="center">0</td></tr><tr><td align="center">2</td><td align="center">52</td><td align="center">I</td><td align="left">Squamous cell</td><td align="left">Post-menopause</td><td align="left">Disease-free</td><td align="center">76.01</td></tr><tr><td align="center">3</td><td align="center">49</td><td align="center">I</td><td align="left">Squamous cell</td><td align="left">Menopause</td><td align="left">Disease</td><td align="center">203.36</td></tr><tr><td align="center">4</td><td align="center">44</td><td align="center">I</td><td align="left">Squamous cell</td><td align="left">Pre-menopause</td><td align="left">Disease-free</td><td align="center">0</td></tr><tr><td align="center">5</td><td align="center">65</td><td align="center">I</td><td align="left">Squamous cell</td><td align="left">Post-menopause</td><td align="left">Disease-free</td><td align="center">0</td></tr><tr><td align="center">6</td><td align="center">67</td><td align="center">I</td><td align="left">Squamous cell</td><td align="left">Post-menopause</td><td align="left">Disease-free</td><td align="center">86.53</td></tr><tr><td align="center">7</td><td align="center">47</td><td align="center">I</td><td align="left">Squamous cell</td><td align="left">Menopause</td><td align="left">Disease-free</td><td align="center">65.3</td></tr><tr><td align="center">8</td><td align="center">34</td><td align="center">I</td><td align="left">Squamous cell</td><td align="left">Pre-menopause</td><td align="left">Disease-free</td><td align="center">66.45</td></tr><tr><td align="center">9</td><td align="center">49</td><td align="center">II</td><td align="left">Squamous cell</td><td align="left">Menopause</td><td align="left">Disease-free</td><td align="center">78.44</td></tr><tr><td align="center">10</td><td align="center">63</td><td align="center">II</td><td align="left">Squamous cell</td><td align="left">Post-menopause</td><td align="left">Disease-free</td><td align="center">0</td></tr><tr><td align="center">11</td><td align="center">38</td><td align="center">II</td><td align="left">Squamous cell</td><td align="left">Menopause</td><td align="left">Disease-free</td><td align="center">0</td></tr><tr><td align="center">12</td><td align="center">48</td><td align="center">II</td><td align="left">Squamous cell</td><td align="left">Menopause</td><td align="left">Disease-free</td><td align="center">0</td></tr><tr><td align="center">13</td><td align="center">55</td><td align="center">II</td><td align="left">Squamous cell</td><td align="left">Post-menopause</td><td align="left">Disease-free</td><td align="center">0</td></tr><tr><td align="center">14</td><td align="center">35</td><td align="center">II</td><td align="left">Squamous cell</td><td align="left">Pre-menopause</td><td align="left">Disease-free</td><td align="center">166.25</td></tr><tr><td align="center">15</td><td align="center">66</td><td align="center">II</td><td align="left">Squamous cell</td><td align="left">Post-menopause</td><td align="left">Disease</td><td align="center">0</td></tr><tr><td align="center">16</td><td align="center">52</td><td align="center">II</td><td align="left">Squamous cell</td><td align="left">Post-menopause</td><td align="left">Disease</td><td align="center">0</td></tr><tr><td align="center">17</td><td align="center">80</td><td align="center">II</td><td align="left">Squamous cell</td><td align="left">Post-menopause</td><td align="left">Disease</td><td align="center">0</td></tr><tr><td align="center">18</td><td align="center">70</td><td align="center">II</td><td align="left">Squamous cell</td><td align="left">Post-menopause</td><td align="left">Disease-free</td><td align="center">0</td></tr><tr><td align="center">19</td><td align="center">65</td><td align="center">II</td><td align="left">Squamous cell</td><td align="left">Post-menopause</td><td align="left">Disease</td><td align="center">0</td></tr><tr><td align="center">20</td><td align="center">39</td><td align="center">II</td><td align="left">Squamous cell</td><td align="left">Pre-menopause</td><td align="left">Disease</td><td align="center">70.42</td></tr><tr><td align="center">21</td><td align="center">57</td><td align="center">II</td><td align="left">Squamous cell</td><td align="left">Post-menopause</td><td align="left">Disease-free</td><td align="center">55.45</td></tr><tr><td align="center">22</td><td align="center">37</td><td align="center">II</td><td align="left">Squamous cell</td><td align="left">Pre-menopause</td><td align="left">Disease-free</td><td align="center">0</td></tr><tr><td align="center">23</td><td align="center">59</td><td align="center">II</td><td align="left">Squamous cell</td><td align="left">Post-menopause</td><td align="left">Disease</td><td align="center">0</td></tr><tr><td align="center">24</td><td align="center">36</td><td align="center">II</td><td align="left">Squamous cell</td><td align="left">Pre-menopause</td><td align="left">Disease</td><td align="center">0</td></tr><tr><td align="center">25</td><td align="center">33</td><td align="center">III</td><td align="left">Adenocarcinome</td><td align="left">Pre-menopause</td><td align="left">Dead</td><td align="center">0</td></tr><tr><td align="center">26</td><td align="center">50</td><td align="center">III</td><td align="left">Adenocarcinome</td><td align="left">Post-menopause</td><td align="left">Dead</td><td align="center">0</td></tr><tr><td align="center">27</td><td align="center">60</td><td align="center">III</td><td align="left">Squamous cell</td><td align="left">Post-menopause</td><td align="left">Disease-free</td><td align="center">0</td></tr><tr><td align="center">28</td><td align="center">64</td><td align="center">III</td><td align="left">Adenocarcinome</td><td align="left">Post-menopause</td><td align="left">Dead</td><td align="center">0</td></tr><tr><td align="center">29</td><td align="center">80</td><td align="center">III</td><td align="left">Squamous cell</td><td align="left">Post-menopause</td><td align="left">Dead</td><td align="center">0</td></tr><tr><td align="center">30</td><td align="center">52</td><td align="center">III</td><td align="left">Squamous cell</td><td align="left">Post-menopause</td><td align="left">Disease-free</td><td align="center">173.96</td></tr><tr><td align="center">31</td><td align="center">56</td><td align="center">III</td><td align="left">Squamous cell</td><td align="left">Post-menopause</td><td align="left">Disease-free</td><td align="center">0</td></tr><tr><td align="center">32</td><td align="center">70</td><td align="center">III</td><td align="left">Squamous cell</td><td align="left">Post-menopause</td><td align="left">Disease-free</td><td align="center">81.5</td></tr><tr><td align="center">33</td><td align="center">72</td><td align="center">III</td><td align="left">Adenosquamous</td><td align="left">Post-menopause</td><td align="left">Dead</td><td align="center">0</td></tr><tr><td align="center">34</td><td align="center">33</td><td align="center">III</td><td align="left">Squamous cell</td><td align="left">Pre-menopause</td><td align="left">Disease</td><td align="center">0</td></tr><tr><td align="center">35</td><td align="center">82</td><td align="center">III</td><td align="left">Adenocarcinome</td><td align="left">Post-menopause</td><td align="left">Disease</td><td align="center">0</td></tr><tr><td align="center">36</td><td align="center">48</td><td align="center">III</td><td align="left">Squamous cell</td><td align="left">Menopause</td><td align="left">Disease-free</td><td align="center">0</td></tr><tr><td align="center">37</td><td align="center">32</td><td align="center">III</td><td align="left">Squamous cell</td><td align="left">Pre-menopause</td><td align="left">Disease</td><td align="center">98.59</td></tr><tr><td align="center">38</td><td align="center">48</td><td align="center">III</td><td align="left">Squamous cell</td><td align="left">Menopause</td><td align="left">Disease</td><td align="center">0</td></tr><tr><td align="center">39</td><td align="center">36</td><td align="center">III</td><td align="left">Adenosquamous</td><td align="left">Pre-menopause</td><td align="left">Disease</td><td align="center">0</td></tr><tr><td align="center">40</td><td align="center">52</td><td align="center">III</td><td align="left">Squamous cell</td><td align="left">Post-menopause</td><td align="left">Disease-free</td><td align="center">0</td></tr><tr><td align="center">41</td><td align="center">67</td><td align="center">III</td><td align="left">Squamous cell</td><td align="left">Post-menopause</td><td align="left">Disease-free</td><td align="center">88.95</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Smac positivity in cervical cancer tumor samples.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Variable</bold></td><td align="center">No. Patients (n = 41)</td><td align="center">Smac Positive (n = 13)</td><td align="center">Smac Negative (n = 28)</td><td align="center"><bold>
                           <italic>P</italic>
                        </bold></td></tr></thead><tbody><tr><td align="center"><bold>Age</bold></td><td align="center">53.36 (32&#x02013;82)</td><td align="center">50</td><td align="center">54.92</td><td align="center">0.3</td></tr><tr><td align="center" colspan="5"><bold>Stage</bold></td></tr><tr><td align="center">IB</td><td align="center">8</td><td align="center">5</td><td align="center">3</td><td></td></tr><tr><td align="center">IIB</td><td align="center">16</td><td align="center">4</td><td align="center">12</td><td align="center">0.11</td></tr><tr><td align="center">IIIB</td><td align="center">17</td><td align="center">4</td><td align="center">13</td><td></td></tr><tr><td align="center" colspan="5"><bold>Histology of tumors</bold></td></tr><tr><td align="center">Squamous cell</td><td align="center">34</td><td align="center">13</td><td align="center">21</td><td></td></tr><tr><td align="center">Adenocarcinoma</td><td align="center">5</td><td align="center">0</td><td align="center">5</td><td align="center">0.14</td></tr><tr><td align="center">Adenosquamous</td><td align="center">2</td><td align="center">0</td><td align="center">2</td><td></td></tr><tr><td align="center" colspan="5"><bold>Menopausal status</bold></td></tr><tr><td align="center">Pre-Menopause</td><td align="center">12</td><td align="center">5</td><td align="center">7</td><td></td></tr><tr><td align="center">Menopause</td><td align="center">6</td><td align="center">2</td><td align="center">4</td><td align="center">0.64</td></tr><tr><td align="center">Post-Menopause</td><td align="center">23</td><td align="center">6</td><td align="center">17</td><td></td></tr><tr><td align="center" colspan="5"><bold>Current status</bold></td></tr><tr><td align="center">Disease free</td><td align="center">21</td><td align="center">9</td><td align="center">12</td><td></td></tr><tr><td align="center">Diseased</td><td align="center">15</td><td align="center">4</td><td align="center">11</td><td align="center">0.15</td></tr><tr><td align="center">Dead</td><td align="center">5</td><td align="center">0</td><td align="center">5</td><td></td></tr></tbody></table></table-wrap></sec></back></article>



